Patent intelligence · US
US 7112342
Enriched platelet wound healant
Enriched platelet wound healant
Patent details — US 7112342
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 26, 2006
- Expiration
- Sep 21, 2026
- Applicant
- Cytomedix, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K31/00, A61K35/19, A61K38/4833
Quick answer
US 7112342 (Enriched platelet wound healant) is held by Cytomedix, Inc.. Status: granted. Granted Sep 26, 2006. Expires Sep 21, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cytomedix, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K31/00, A61K35/19, A61K38/4833
More from Cytomedix, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 7112342?
US 7112342 (Enriched platelet wound healant) is held by Cytomedix, Inc.. Status: granted. Granted Sep 26, 2006. Expires Sep 21, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7112342?
Cytomedix, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 7112342 expire?
Our index shows an expiration date of Sep 21, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.